Concord Biotech Limited (BOM:543960)
India flag India · Delayed Price · Currency is INR
1,420.30
+87.10 (6.53%)
At close: Jul 31, 2026

Concord Biotech Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
2,6093,7163,0812,4011,749
Depreciation & Amortization
744.58543.61535.43538.94498.96
Other Amortization
0.010.130.491.391.55
Loss (Gain) From Sale of Assets
-0.132.25-0.120.940.34
Loss (Gain) From Sale of Investments
-211.28-222.64-140.65-37.17-52.3
Loss (Gain) on Equity Investments
-29.0913.22-33.71-19.5936.38
Provision & Write-off of Bad Debts
27.5817.846.690.92-3.46
Other Operating Activities
-332.6981.9117.3196.5971.19
Change in Accounts Receivable
704.53-1,708-786.6-430.97-527.69
Change in Inventory
-866.89-317.1343.61-172.27-415.12
Change in Accounts Payable
-85.2220.89-112.8798.81365.35
Change in Other Net Operating Assets
108.3396.5444.06-18.42356.91
Operating Cash Flow
2,6692,4452,6552,4602,081
Operating Cash Flow Growth
9.15%-7.89%7.91%18.19%24.77%

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-951.51-1,112-856.89-1,451-1,555
Sale of Property, Plant & Equipment
11.991.750.250.56
Investment in Securities
-500.71-520.08-718.69-184.76395.22
Other Investing Activities
23.9829.9527.7355.8541.4
Investing Cash Flow
-1,427-1,600-1,546-1,580-1,118

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Repaid
-3.81-58.49--43.37-
Long-Term Debt Repaid
-2.73-8.97-265.04-265.96-266.56
Total Debt Repaid
-6.54-67.45-265.04-309.33-266.56
Net Debt Issued (Repaid)
-6.54-67.45-265.04-309.33-266.56
Common Dividends Paid
-1,119-915.39-714.53-535.64-705.21
Other Financing Activities
-2.83-4.84-12.58-7.23-22.26
Financing Cash Flow
-1,129-987.68-992.15-852.19-994.02

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Miscellaneous Cash Flow Adjustments
---0--14.29
Net Cash Flow
112.82-142.38116.4328.32-44.77

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
1,7171,3331,7981,009526.36
Free Cash Flow Growth
28.79%-25.83%78.14%91.72%-
Free Cash Flow Margin
16.28%11.11%17.68%11.83%7.38%
Free Cash Flow Per Share
16.4112.7517.189.655.03
Levered Free Cash Flow
1,374943.221,178505.95188.91
Unlevered Free Cash Flow
1,375946.531,194534.14223.18

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
2.836.3326.539.5853.15
Cash Income Tax Paid
1,0041,0941,033702.77607.85
Change in Working Capital
-139.23-1,708-811.8-522.86-220.55